| Literature DB >> 30117204 |
Giulia Pastorino1, Laura Cornara1,2, Sónia Soares3, Francisca Rodrigues3, M Beatriz P P Oliveira3.
Abstract
In the last years, consumers are paying much more attention to natural medicines and principles, mainly due to the general sense that natural compounds are safe. On the other hand, there is a growing demand by industry for plants used in traditional medicine that could be incorporated in foods, nutraceuticals, cosmetics, or even pharmaceuticals. Glycyrrhiza glabra Linn. belongs to the Fabaceae family and has been recognized since ancient times for its ethnopharmacological values. This plant contains different phytocompounds, such as glycyrrhizin, 18β-glycyrrhetinic acid, glabrin A and B, and isoflavones, that have demonstrated various pharmacological activities. Pharmacological experiments have demonstrated that different extracts and pure compounds from this species exhibit a broad range of biological properties, including antibacterial, anti-inflammatory, antiviral, antioxidant, and antidiabetic activities. A few toxicological studies have reported some concerns. This review addresses all those issues and focuses on the pharmacological activities reported for G. glabra. Therefore, an updated, critical, and extensive overview on the current knowledge of G. glabra composition and biological activities is provided here in order to explore its therapeutic potential and future challenges to be utilized for the formulation of new products that will contribute to human well-being.Entities:
Keywords: Glycyrrhiza glabra; pharmacology; phytochemistry; toxicology; traditional use
Mesh:
Substances:
Year: 2018 PMID: 30117204 PMCID: PMC7167772 DOI: 10.1002/ptr.6178
Source DB: PubMed Journal: Phytother Res ISSN: 0951-418X Impact factor: 5.878
Chemical structure of the most important compounds of
| Compounds | Chemical structures |
|---|---|
| Liquiritin |
|
| Isoliquiritin |
|
| Glycyrrhizin |
|
| Liquiritigenin |
|
| Isoliquiritigenin |
|
| 18β‐Glycyrrhetinic acid |
|
| Liquiritin apioside |
|
| Glycyrrhetic acid |
|
| Licochalcone A |
|
| Glabridin |
|
Summary of the key studies conducted with liquorice‐derived compounds or extract
| Property | Compound | Concentration | Method | Major findings | Reference |
|---|---|---|---|---|---|
| Neuroprotective activity | Glabridin | 5–50 mg/kg | In vivo—oral administration to mice | Improvement of learning and memory in nondiabetic rats; it reversed learning and memory deficits of diabetic rats. Low‐dose glabridin did not alter cognitive function | (Hasanein, |
|
| 75–300 mg/kg, 7 days | In vivo—oral administration to Swiss young male albino mice | Production of antidepressant‐like effect in mice in forced swim test and tail suspension test, probably by interaction with adrenergic and dopaminergic system | (Dhingra & Sharma, | |
|
| 75–300 mg/kg, 7 days | In vivo—oral administration to mice | Dose of 150 mg/kg significantly improved learning and memory of mice | (Parle, Dhingra, & Kulkarni, | |
| Sedative activity | Glabridin | 10−12–10−8 M | In vivo—acutely isolated dorsal raphe neurons of a rat | Sedative and hypnotic effects by potentiating GABAergic inhibition in dorsal raphe neurons by GABAA receptor | (Jin et al., |
| 30 μM | In vitro— | Strong potentiating effect on GABAA α1β(1−3)γ2 receptors | (Cho et al., | ||
| Antidepressive activity |
| 75–300 mg/kg | In vivo—forced swim test and tail suspension test applied to mice | Antidepressant‐like effect of liquorice extract seems to be mediated by increase of brain norepinephrine and dopamine, but not by increase of serotonin | (Dhingra & Sharma, |
| Oestrogenic activity | 18β‐Glycyrrhetinic acid | 0–200 μM | In vitro—human breast cancer cells (MCF‐7) | Induction of apoptosis in human breast carcinoma MCF‐7 cells via caspase activation and modulation of Akt/FOXO3a pathway | (Sharma, Kar, Palit, & Das, |
| Glabridin | 1 nM–10 μM | In vitro—endometrial cell line (Ishikawa cells) | Activation of ER‐α‐SRC‐1‐co‐activator complex, which displays a dose‐dependent increase in oestrogenic activity | (Su Wei Poh, Voon Chen Yong, Viseswaran, & Chia, | |
| 1 nM–25 μM | In vitro—human breast cancer cells (T‐47D, MCF‐7, and MDA‐MB‐468) | Inhibition of the growth of breast cancer cells | (Su Wei Poh et al., | ||
| 50 μg, 3–14 days | In vivo—daily feeding of prepubertal female Wistar rats | Stimulation of creatine kinase specific activity | (Tamir, Eizenberg, Somjen, Izrael, & Vaya, | ||
| Liquorice root extract | 25 μg/day, 2 weeks | In vivo—oral administration to female rats | Increase in creatine kinase activity | (Tamir et al., | |
| Liquiritigenin | 2–10 μg/ml | In vitro—MCF‐7 and T47D cells | Induction of oestrogen responsive alkaline phosphatase activity in endometrial cancer cells, oestrogen responsive element luciferase in MCF‐7 cells and | (Somjen et al., | |
| Isoliquiritigenin | 0–0.04 mg/ml | In vivo—intraperitoneal injection of female ICR mice | Improvement of IVF rate | (Tung, Shoyama, Wada, & Tanaka, | |
| Skin effects | Glycyrrhizinic acid | 20%, 2 weeks | In vivo—double‐blind clinical trial in human patients | Reduction of erythema, oedema, and itching scores | (Halder & Richards, |
| — | In vitro—topical treatments in human patients during 4 weeks | Lighten hand solar lentigines | (Nerya et al., | ||
| Glycyrrhetinic acid; glabridin | 0–120 μM | In vitro—human keratinocyte culture | Prevention of oxidative DNA fragmentation and activation of apoptosis‐associated proteins in human keratinocyte | (Grippaudo & Di Russo, | |
| Glabridin; glabrene; isoliquiritigenin | 0.7 μM (glabridin), 7 μM (glabrene), and 26 μM (isoliquiritigenin) | In vitro—human melanocyte (G361) | Inhibition on tyrosinase‐dependent melanin biosynthesis | (Parvez, Kang, Chung, & Bae, | |
| Liquorice hydro‐alcoholic extract | 1–2% | In vivo—Wistar albino rats | Potentiation of hair growth activity | (Veratti et al., | |
| Antiviral activity | Glycyrrhizin | 10 mg/kg (compound) |
In vitro—Vero cells In vivo—ducks | Stimulation of immune and antiviral effect against DHV | (Soufy et al., |
| 0.1 μg/ml (extract) | In vitro—human foreskin cell line | Protection of host cells against EV71 infection | (Kuo, Chang, Wang, & Chiang, | ||
| 316–625 mg/L (compound) | In vitro—Vero cells | Protection against coronavirus | (Cinatl et al., | ||
| 100 μg/ml (compound) | In vitro—peripheral blood mononuclear cells | Inhibition of nonsyncytium‐inducing variant of HIV replication | (Sasaki, Takei, Kobayashi, Pollard, & Suzuki, | ||
| 400–1,600 mg/day (compound) | In vitro—human immunodeficiency virus type 1 (HIV‐1) P24 antigen | Inhibition of HIV‐1 replication | (Hattori et al., | ||
| 80, 160, 240 mg 3× per week or 200 mg 6× per week | In vivo—human patients (intravenous) | Treatment of chronic hepatitis C infection | (van Rossum, Vulto, Hop, & Schalm, | ||
| 100 mg/day | In vivo—human patients (intravenous) | Prevention of autoimmune hepatitis progression | (Yasui et al., | ||
| 25–200 μg/ml | In vitro—lung epithelial A549 cells | Reduction of pathogenic H5N1 influenza A virus replication | (Michaelis et al., | ||
| Anticarcinogenic activity | Glabridin | 0–10 μM, 24, 48, and 72 hr | In vitro—cancer stem cells (CSCs) | Reduction of CSC‐like properties, enhancing the effectiveness of breast cancer therapy | (Jiang et al., |
| 0–20 mg/kg, 4 weeks | In vivo—BALB/c nude mice | ||||
| 0–100 μM (compound) | In vitro—human hepatic cell lines (Huh7, HepG2, Sk‐Hep‐1) | Induction of apoptosis in Huh7 cells | (Hsieh et al., | ||
| Licochalcone E | 12.5–50 μM (compound) | In vitro—human oral keratinocytes and human pharyngeal squamous carcinoma cell line | Induction of FaDu cell death | (Yu et al., | |
| Licochalcone A | 0–500 μM (compound) | In vitro—human gastric cancer cell lines (MKN‐28, AGS, MKN‐45) | Induction of apoptosis of gastric cancer cell via the caspase‐dependent mitochondrial pathway | (Xiao et al., | |
| Antimicrobial activity | Glabridin | 3.12–25 μg/ml | MIC | Inhibition of the growth of clinical isolates of multidrug‐resistant | (Fukai et al., |
| 3.13–12.5 μg/ml | MIC | ||||
| 29.16 μg/ml | MIC | Decrease of | (Gupta et al., | ||
| Glycyrrhetinic acid | 62.5–1.024 mg/L | MIC | Inhibition of the growth of clinical isolates of multidrug‐resistant | (Oyama et al., | |
| 100–400 μg/ml | MIC, MBC | Decrease of | (Chakotiya, Tanwar, Narula, & Sharma, | ||
| ≤50 mg/L | MIC | Decrease of | (Krausse, Bielenberg, Blaschek, & Ullmann, | ||
| Antioxidant activity | Glabridin | 3.12–25 μg/ml | DPPH, FRAP, SOD | Protection of low‐density lipoprotein from oxidation | (Singh et al., |
| 60 mg | In vivo—oral administration to humans (LDL isolation) | (Carmeli & Fogelman, | |||
| Licochalcone | 2–20 μg/ml | DPPH, superoxide anion, lipid peroxidation, red blood cells | Inhibition of the microsomal lipid peroxidation | (Haraguchi, Ishikawa, Mizutani, Tamura, & Kinoshita, | |
| Hepatoprotective activity | Liquorice aqueous extract | 100–300 mg/kg 15 days | In vivo—oral administration to Wistar rats | Stimulation of the antioxidant enzymes and arrest of inflammatory cytokine production | (Huo, Wang, Liang, Bao, & Gu, |
|
| 2 g/day, 2 months | In vivo—humans | ALT and AST decrease | (Hajiaghamohammadi, Ziaee, & Samimi, | |
| 10, 30, 100 mg/kg |
In vivo—BALB/c mice In vitro—RAW 264.7 macrophages | Protection against LPS fulminant hepatic failure | (Yin et al., | ||
| Glycyrrhetinic acid | 0.5–20 μM | Metabolomics | Decrease of inflammation in RAW 264.7 cells | (Liu et al., | |
| Anti‐inflammatory activity | Glabridin | 75 mg/kg | In vivo—oral administration to mice | Decrease of MIP 1α expression | (Xiao et al., |
| Glycyrrhizin | 1–100 μM | DPPH, AAPH |
Protection against lipid peroxidation of liposomal membrane Inhibition of ROS | (Rackova et al., | |
| 50–200 μg/ml | LPS inflammatory mediators production (TNF‐α, IL‐1β, COX‐2, PG2) | Decrease of endometriosis | (X. R. Wang, et al., | ||
| 10, 20, 100 mg/kg | In vivo—mice | Decrease of LPS inflammatory mediators | (Yin et al., |
Note. ALT: alanine aminotransferase; AST: aspartate aminotransferase; DHV: duck hepatitis virus; FRAP: ferric reducing antioxidant potential; ICR: Institute of Cancer Research; IVF: in vitro fertilization; LDL: low‐density lipoprotein; LPS: lipopolysaccharide; MBC: minimum bactericidal concentration; MIC: minimum inhibitory concentration; ROS; reactive oxygen species; SOD: superoxide dismutase.